A 2011 study noted a decreasing trend in the use of adjuvant interferon α in melanoma patients with regional diseases [from 26% (1995) to 21% (2001)], suggesting a lack of consensus for adjuvant therapy use in community settings in the interferon adjuvant treatment era 13 .
← all excerpts
Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
1
—
—